Education
About Us
Working with TipRanks
Follow Us
Hyperfine (HYPR)
NASDAQ:HYPR
Top Page
Hyperfine
(NASDAQ:HYPR)
57Neutral
Hyperfine (HYPR) vs. S&P 500 (SPY)
Market Cap
$71.19M
Dividend YieldN/A
Average Volume (3M)560.12K
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue Growth35.67%
EPS Growth13.34%
CountryUS
Employees131
SectorHealthcare
Sector Strength77
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-0.57
Shares Outstanding62,404,736
10 Day Avg. Volume232,322
30 Day Avg. Volume560,123
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.06
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1.10Price Target Upside19.57% Upside
Rating ConsensusHold
Number of Analyst Covering1
Hyperfine Business Overview & Revenue Model
Company DescriptionHealthCor Catalio Acquisition Corp is a blank check company.
How the Company Makes MoneyHyperfine makes money primarily through the sale and lease of its portable MRI systems, Swoop. The company's revenue model is based on a combination of direct sales to healthcare providers and leasing agreements that offer flexibility for facilities looking to incorporate advanced imaging technologies without significant upfront costs. Additionally, Hyperfine may generate recurring revenue through service agreements, maintenance contracts, and software updates for their imaging systems. Partnerships with hospitals, clinics, and research institutions are significant for expanding their market reach and adoption of their innovative MRI technology.
Hyperfine Financial Statement Overview
Summary
Hyperfine exhibits strong revenue growth and a solid equity position, but persistent profitability and cash flow issues present significant challenges. The company is expanding sales but must improve operational efficiency and cash management to achieve sustainable financial health.Income Statement
Hyperfine's TTM (Trailing-Twelve-Months) revenue growth is strong at 20.13%, indicating a positive trend in sales. However, the company struggles with profitability, as evidenced by negative margins: Gross Profit Margin is 46.00%, but both the Net Profit Margin and EBIT Margin are negative at -309.50% and -332.57%, respectively. The negative EBITDA Margin of -324.76% further highlights the challenges in achieving operational efficiency.45
Neutral
Balance Sheet
The company maintains a healthy equity position with an Equity Ratio of 84.08% and a very low Debt-to-Equity Ratio of 0.002, indicating minimal reliance on debt financing. However, the negative Return on Equity (ROE) of -70.32% signals a significant challenge in generating profits from shareholders' investments.55
Neutral
Cash Flow
Hyperfine's cash flow situation is concerning, with negative Free Cash Flow and a declining Free Cash Flow Growth Rate of 3.82%, indicating cash burn. The Operating Cash Flow to Net Income Ratio is 0.98, suggesting that operating cash flow closely mirrors the negative net income, highlighting liquidity challenges.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 13.26M | 11.03M | 6.81M | 1.50M | 294.00K | 0.00 | Gross Profit |
| 6.10M | 4.76M | 907.00K | -1.17M | -477.00K | 0.00 | EBIT |
| -44.09M | -48.12M | -73.87M | -64.87M | -23.49M | -19.97M | EBITDA |
| -43.05M | -47.06M | -72.86M | -64.14M | -23.20M | -19.83M | Net Income Common Stockholders |
| -41.01M | -44.24M | -72.45M | -64.83M | -23.36M | -18.79M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 26.44M | 75.18M | 117.47M | 188.50M | 62.68M | 26.44M | Total Assets |
| 0.00 | 94.20M | 134.05M | 202.47M | 71.53M | 30.57M | Total Debt |
| 0.00 | 185.00K | 0.00 | 0.00 | 178.00K | 0.00 | Net Debt |
| 26.44M | -75.00M | -117.47M | -188.50M | -62.50M | -26.44M | Total Liabilities |
| 0.00 | 9.80M | 10.33M | 16.25M | 132.58M | 70.44M | Stockholders Equity |
| 28.78M | 84.40M | 123.72M | 186.23M | -61.05M | -39.86M |
| Cash Flow | Free Cash Flow | ||||
| -40.98M | -42.61M | -72.92M | -49.89M | -23.09M | -18.62M | Operating Cash Flow |
| -40.35M | -41.81M | -72.34M | -47.18M | -21.52M | -18.37M | Investing Cash Flow |
| -633.00K | -804.00K | -585.00K | -2.71M | -1.57M | -244.00K | Financing Cash Flow |
| 993.00K | 174.00K | 7.00K | 176.77M | 60.94M | 4.74M |
Hyperfine Technical Analysis
Negative
0.92
Price Trends
1.06
Negative
1.01
Negative
1.01
Negative
Market Momentum
-0.06
Positive
42.07
Neutral
48.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Negative. The current price of 0.92 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.06, and below the 200-day MA of 1.01, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 42.07 is Neutral, neither overbought nor oversold. The STOCH value of 48.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYPR.
Hyperfine Risk Analysis
Hyperfine disclosed 76 risk factors in its most recent earnings report. Hyperfine reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Hyperfine Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $2.31B | 67.84 | 19.39% | ― | 82.74% | ― | |
61 Neutral | $3.16B | ― | -75.27% | ― | 20.13% | 10.05% | |
57 Neutral | $71.19M | ― | -53.93% | ― | 35.67% | 13.34% | |
49 Neutral | $6.86B | 0.03 | -55.16% | 2.48% | 24.39% | -2.90% | |
43 Neutral | $2.14B | ― | -46.67% | ― | 18.82% | 19.76% | |
36 Underperform | $438.04K | ― | 52.08% | ― | -32.57% | -15.03% |
* Healthcare Sector Average
Performance Comparison
HYPR
Hyperfine
1.28
0.09
7.56%
CUTR
Cutera
0.02
-1.81
-98.91%
NVCR
NovoCure
19.59
5.77
41.75%
IRTC
Irhythm Technologies
103.70
1.41
1.38%
TMDX
TransMedics Group
67.69
-6.47
-8.72%
Hyperfine Earnings Call Summary
Earnings Call Date: Mar 17, 2025 | % Change Since: -28.13% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Positive
The earnings call presented a strong performance with significant revenue growth, gross margin expansion, and successful international expansion. However, the company still faces challenges with net losses and cash burn. The overall sentiment is positive, driven by technological advancements, clinical study successes, and strategic market expansion.Highlights
Strong Revenue Growth
Hyperfine reported revenue of $3.6 million for Q3 2024, representing a 56% year-over-year growth. Year-to-date revenue is $10.6 million, up 27% from the first 9 months of 2023.
Gross Margin Expansion
The company achieved a gross margin of 52% for Q3 2024, a record level, with year-to-date gross margin at 48%, representing over 330 basis points of expansion from the first 9 months of 2023.
FDA Clearance for AI-Powered Software
Hyperfine received FDA clearance for its ninth generation AI-powered software, which improves image quality and reduces acquisition times.
International Expansion
Hyperfine expanded its distribution network in the European markets and obtained CE approval for its latest generation software.
Promising Clinical Study Results
The Swoop system showed promising results in detecting ARIA complications and acute stroke diagnosis, supporting its use in Alzheimer's and stroke care.
Lowlights
Net Loss
Net loss for Q3 2024 was $10.3 million, slightly improved from $10.8 million in Q3 2023.
Cash Burn
Year-to-date cash burn was $30.2 million, with an anticipated total cash burn of $37 million to $40 million for the full year 2024.
Company Guidance
During the Q3 2024 earnings call for Hyperfine, executives provided guidance and shared several key metrics. The company reported a revenue of $3.6 million, marking a 56% year-over-year growth, and achieved a gross margin of 52%, which reflects over 270 basis points of sequential expansion. For the full year 2024, Hyperfine narrowed its revenue outlook to a range of $14 million to $14.5 million, expecting approximately 30% year-over-year growth. The gross margin for 2024 is anticipated to range between 47% and 50%. Despite a net loss of $10.3 million, equivalent to $0.14 per share, the company highlighted successful expense management and cost-saving initiatives that have contributed to a reduction in cash burn, expected to be between $37 million and $40 million for the year. The company is confident in surpassing a 50% gross margin sustainably, driven by strategic expansion and technological advancements.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.